| Business Summary | | BICO,
Incorporated's
primary
business
is
the
development
and
manufacture
of
new
devices,
which
include
models
of
a
non-invasive
glucose
sensor,
procedures
relating
to
the
use
of
regional
extracorporeal
hyperthermia
in
the
treatment
of
cancer
and
environmental
products
that
help
to
clean
up
oil
spills.
The
Company's
non-invasive
glucose
sensor
helps
diabetics
measure
their
glucose
without
pricking
their
fingers
or
having
to
draw
blood.
Regional
extracorporeal
hyperthermia
is
a
system
that
recirculates
the
patient's
blood
in
a
specific
area
of
the
body
after
the
blood
has
been
heated
outside
the
body.
The
recirculated
blood's
higher
temperature
helps
treat
certain
diseases
by
inducing
an
artificial
fever
that
kills
targeted
cells.
The
Company's
Petroleum
Remediation
Product
is
designed
as
an
environmental
microbial
microcapsule,
which
is
used
to
collect,
contain
and
separate
oil-type
products
in
or
from
water. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BIKO
and
its
subsidiaries
are
engaged
in
the
development,
manufacturing
and
marketing
of
biomedical
products
and
biological
remediation
products.
For
the
six
months
ended
6/01,
revenues
totalled
$1.4
million,
up
from
$39
thousand.
Net
loss
applicable
to
Common
increased
16%
to
$18.3
million.
Revenues
reflect
increased
biomedication
production.
Higher
loss
reflects
increased
salaries
and
professional
services
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Fred Cooper, 54 CEO
and Exec. VP | $1.3M | Michael Thompson, 50 CFO | 103K | Anthony Feola, 52 Sr.
VP, Direcotr | 902K | Glenn Keeling, 49 VP
of Marketing, Director | 593K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|